Sei Investments Co. lifted its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 3.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 332,431 shares of the biotechnology company’s stock after buying an additional 9,809 shares during the quarter. Sei Investments Co.’s holdings in Biogen were worth $105,904,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Bank of New York Mellon Corp lifted its stake in shares of Biogen by 24.0% during the 3rd quarter. Bank of New York Mellon Corp now owns 2,325,987 shares of the biotechnology company’s stock valued at $728,314,000 after buying an additional 450,207 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Biogen by 35.1% during the 3rd quarter. Ameriprise Financial Inc. now owns 2,309,394 shares of the biotechnology company’s stock valued at $723,142,000 after buying an additional 600,384 shares in the last quarter. Jackson Square Partners LLC lifted its stake in shares of Biogen by 9.3% during the 3rd quarter. Jackson Square Partners LLC now owns 2,249,253 shares of the biotechnology company’s stock valued at $704,286,000 after buying an additional 191,526 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Biogen by 1.6% during the 3rd quarter. Legal & General Group Plc now owns 1,089,590 shares of the biotechnology company’s stock valued at $341,155,000 after buying an additional 16,871 shares in the last quarter. Finally, American Century Companies Inc. lifted its stake in shares of Biogen by 10.5% during the 4th quarter. American Century Companies Inc. now owns 1,001,387 shares of the biotechnology company’s stock valued at $319,012,000 after buying an additional 95,432 shares in the last quarter. Institutional investors own 87.79% of the company’s stock.

A number of analysts recently commented on BIIB shares. Piper Jaffray Companies restated a “buy” rating and set a $390.00 price target on shares of Biogen in a research note on Monday, December 18th. Nomura upped their price target on shares of Biogen from $355.00 to $420.00 and gave the company a “buy” rating in a research note on Friday, December 22nd. Royal Bank of Canada restated a “hold” rating and set a $321.00 price target on shares of Biogen in a research note on Tuesday, December 5th. SunTrust Banks restated a “buy” rating and set a $354.00 price target on shares of Biogen in a research note on Tuesday, October 24th. Finally, Canaccord Genuity started coverage on shares of Biogen in a research note on Friday, October 27th. They set a “hold” rating and a $340.00 price target on the stock. Eight research analysts have rated the stock with a hold rating and twenty-four have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $368.99.

In related news, Director Alexander J. Denner purchased 30,000 shares of the firm’s stock in a transaction dated Wednesday, November 29th. The shares were purchased at an average price of $317.36 per share, with a total value of $9,520,800.00. Following the acquisition, the director now directly owns 10,029 shares of the company’s stock, valued at $3,182,803.44. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Robert W. Pangia sold 5,832 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total transaction of $1,922,518.80. Following the completion of the transaction, the director now directly owns 23,539 shares in the company, valued at approximately $7,759,631.35. The disclosure for this sale can be found here. Insiders bought a total of 31,560 shares of company stock worth $10,020,858 in the last three months. Insiders own 0.25% of the company’s stock.

Biogen Inc (BIIB) opened at $316.99 on Wednesday. The company has a market cap of $66,987.10, a price-to-earnings ratio of 14.52, a PEG ratio of 1.65 and a beta of 0.75. Biogen Inc has a twelve month low of $244.28 and a twelve month high of $370.57. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). The company had revenue of $3.31 billion during the quarter, compared to the consensus estimate of $3.08 billion. Biogen had a return on equity of 38.32% and a net margin of 20.69%. Biogen’s quarterly revenue was up 15.1% on a year-over-year basis. During the same period in the previous year, the company earned $5.04 EPS. equities research analysts expect that Biogen Inc will post 24.88 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international copyright & trademark laws. The correct version of this piece can be viewed at https://theolympiareport.com/2018/02/14/sei-investments-co-acquires-9809-shares-of-biogen-inc-biib.html.

Biogen Profile

Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).

Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.